All Biotech companies at once!

Project information panel

3DNET – Drug Discovery and Development for Novel Eye Therapeutics

Age-related macular degeneration, diabetic retinopathy, and corneal inflammation are significant causes of irreversible blindness with increasing prevalence as the EU population ages and the diabetes epidemic expands. There is an unmet clinical need for more effective treatments to halt or reverse these diseases. Many EU pharmaceutical and biotechnology companies, with established processes for the synthesis and physiochemical characterisation of drugs, have bespoke chemical libraries and lead drugs with potential to treat ocular disease, but lack the expertise and infrastructure to test these drugs in relevant pre-clinical models. In parallel, academic labs with excellent infrastructure to study ocular disease, lack the industry expertise to appropriately develop drugs to enter clinical trials. Thus, clinical development of ocular therapeutics is impeded in the EU due to poor collaboration among academic and industry scientists. 3D-NET establishes a network of industry (Gadea, KalVista & RenaSci) and academic partners (UCD & UVA), who exchange knowledge and people, and whos combined S&T expertise will enhance the discovery and development of drugs that target ocular pathologies (retinal vessel permeability, unwanted blood vessel growth, inflammation and cell degeneration). Novel ophthalmic drugs will be discovered from unbiased screens of small molecules and developed from hits/leads and selected compounds (PI3K-inhs, lipoxins, Kallikrein-inhs, HDAC-inhs, serotonin agonists), on a set of in silico/in vitro/in vivo/ex vivo preclinical models. Expected outputs are: a) enhancing intersectoral training, career development and trans-national mobility of EU researchers, b) high impact publications/priority patent applications and c) overcoming barriers that impede industry-academia partnership in the EU inhibiting the discovery/development of new-cheaper and more effective drugs for ocular disease.

  •  2013-09-01  2017-08-31
  • Overall Cost: 1.66 M.Eur
      > KalVista
      > KalVista Pharmaceuticals
      > RENASCI
  • Other project partners
  • UK ES ES UK 
  • Marie Curie Action: "Industry-Academia Partnerships and Pathways" 
  • Life Sciences 
  • FP7 Data provision: © European Union; Source: CORDIS, Cordis | This page is not provided by the European Commission 

 biotechnology   Pharmaceutical   biotech   research   pharma   Development   diabetes   drug   drugs   in vitro   cell   technology   Bio   chemical   gene   Labor   preclinical   clinical trial   clinical   blood   treatment   synthesis   clinical trials   lab   in vivo   disease   Discovery   career   therapeutic   therapeutics   inflammation   compounds   Small molecule   search   Gen   diseases   pre-clinical   process   training   molecule   Corn   Biotec   industry   molecules   growth   Clinical Development   application   patent   study   oral   compound   Screen   develop   Publications   CARE   companies   lead   small molecules   expertise   Expert   ophthalmic   3D   applications   Leads   vitro   models   ex vivo   permeability   macular degeneration   Collaboration   libraries   target   ipo   Structure   Pathologie   MPO   ABI   Diabetic   diabete   pht   kallikrein   biotechnology   Pharmaceutical   biotech   research   pharma   Development   diabetes   drug   drugs   in vitro   cell   biotechnology   Pharmaceutical   biotech   research   pharma   Development   diabetes   drug   drugs   in vitro   cell   technology   Bio   chemical   gene   Labor   preclinical   clinical trial   clinical   blood   treatment   synthesis   clinical trials   lab   in vivo   disease   Discovery   career   therapeutic   therapeutics   inflammation   compounds   Small molecule   search   Gen   diseases   pre-clinical   process   training   molecule   Corn   Biotec   industry   molecules   growth   Clinical Development   application   patent   study   oral   compound   Screen   develop   Publications   CARE   companies   lead   small molecules   expertise   Expert   ophthalmic   3D   applications   Leads   vitro   models   ex vivo   permeability   macular degeneration   Collaboration   libraries   target   ipo   Structure   Pathologie   MPO   ABI   Diabetic   diabete   pht   kallikrein 

comments powered by Disqus

Report an error:

Did you noticed an error? Please report here...


Top Countries

 DE 933
 UK 761
 NL 663
 IT 616
 FR 516
 BE 315
 ES 306
 CH 305
 SE 237
 AT 179

Top Business Area

 RED 3030
 WHI 1096
 SEL 643
 GRE 489
 CON 311
 ANA 285
 DNA 158
 INF 144
 JOB 36

EU-Projects Champions

 Acreo 41
 Johnson 37
 DSM 32
 Biotec 30
 Tecna 28

Top Legal Types

 LTD 2381
 PLC 1071